TransCode Therapeutics, Inc. (RNAZ)

Compare

0.5409

+0.0459

+(9.27%)

At close: 4:00:01 PM EDT

0.5450

+0.00

+(0.76%)

After hours: 4:44:25 PM EDT

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its Phase I clinical trial has received their initial dose. TransCode also reported that two additional patients in Cohort 4 are scheduled to receive TTX-MC138. The therapeutic candidate being evaluated, TTX-MC138, is TransCode's lead candidate designed to inhibit microRNA-10b, a microRNA critical to the

PR Newswire 5 days ago

RNAZ
+9.27%
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and accompanying warrant, for gross proceeds of approximately $10 million, before

PR Newswire 6 days ago

RNAZ
+9.27%
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has agreed to sell an aggregate of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and associated warrant. The warrants will have an exercise price of $0.86 per share and will be immediately exercisabl

PR Newswire 8 days ago

RNAZ
+9.27%
SRC approves opening of TransCode’s fourth cohort in trial of TTX-MC138

The decision follows the committee’s 'favourable' safety data review of cohort three.

Clinical Trials Arena 18 days ago

RNAZ
+9.27%
TransCode Therapeutics Says Safety Review Committee Approves Opening of Fourth Group in Phase 1 Trial to Treat Metastatic Cancers

TransCode Therapeutics (RNAZ) said Thursday that the Safety Review Committee, monitoring its phase 1

PREMIUM
MT Newswires 19 days ago

RNAZ
+9.27%
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase I clinical trial has unanimously approved opening of the fourth cohort of patients based on the SRC's favorable review of Cohort 3 safety data. The therapeutic candidate being evaluated, TTX-MC138, is a first-in-class therapeutic designed to treat multiple metastatic cancers using an

PR Newswire 19 days ago

RNAZ
+9.27%
TransCode Therapeutics, Inc. Announces Results of Special Meeting

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today held the adjourned session of its Special Meeting from February 4, 2025, (the "Special Meeting"). Shareholders voted upon the two proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission (the "SEC") on December 30, 2024 (t

PR Newswire last month

RNAZ
+9.27%
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate. The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its review of Cohort 1 and 2 safety and pharmacokinetic (PK) data and is monitoring Cohort 3 as prel

PR Newswire last month

RNAZ
+9.27%
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced its Special Meeting scheduled for and convened on February 4, 2025 (the "Special Meeting") has been adjourned until February 25, 2025 at 9:30 a.m. Eastern time (the "Adjourned Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Compa

PR Newswire last month

RNAZ
+9.27%
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 3 of its Phase 1 clinical trial has been dosed with TTX-MC138, its lead candidate. The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its favorable review of Cohort 1 and 2 safety and pharmacokinetic (PK) data. Additional Cohort 3 patients have b

PR Newswire 2 months ago

RNAZ
+9.27%
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from the NASDAQ Stock Market LLC (Nasdaq) that the Company has regained compliance with Listing Rules 5550(a)(2) and 5550(b)(1), the Exchange's minimum bid price and shareholders' equity rules, respectively. The Company has also resolved the violation regarding Listing Rule 5635 (the "Shareholder Approval Rule") by

PR Newswire 2 months ago

RNAZ
+9.27%
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase 1 clinical trial has unanimously approved opening of the third cohort of patients based on its favorable review of Cohort 2 safety data. The therapeutic candidate being evaluated, TTX-MC138, is TransCode's lead candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA critic

PR Newswire 3 months ago

RNAZ
+9.27%
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time December 4, 2024, for its 1-for-33 reverse stock split. TransCode’s common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Decembe

GlobeNewswire 3 months ago

RNAZ
+9.27%
Transcode Therapeutics issues 21.2M shares at 37.7c in private placement

TransCode Therapeutics (RNAZ) has entered into a securities purchase agreement with certain institutional investors. The aggregate gross cash proceeds are expected to be approximately $8M before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the private placement for general corporate purposes and working capital. In connection with the private placement, the Company is planning to issue an aggregate of 2

TipRanks 4 months ago

RNAZ
+9.27%
TransCode Therapeutics, Inc. Announces $8 Million Private Placement

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a securities purchase agreement with certain institutional investors. The aggregate gross cash proceeds are expected to be approximately $8 million before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the

GlobeNewswire 4 months ago

RNAZ
+9.27%
Transcode Therapeutics announces 1-for-33 reverse stock split

TransCode Therapeutics (RNAZ) Board of Directors has approved a 1-for-33 reverse stock split. The reverse stock split was approved by TransCode’s stockholders on November 22, 2024, and is intended to increase the per share trading price of the Company’s common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The 1-for-33 reverse stock split will automatically convert thirty-three current shares of TransCode’s common stoc

TipRanks 4 months ago

RNAZ
+9.27%
TransCode Therapeutics Open Letter to Shareholders

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company: Dear Shareholders, At our upcoming Special Meeting to be held November 22, shareholders are being asked to authorize our Board of Directors to effect a reverse split — only if the Board determines that doing so is necessary as described below. Many shareholders rightly ask why this request. Some believe that the potenti

GlobeNewswire 4 months ago

RNAZ
+9.27%
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from The Nasdaq Stock Market LLC (Nasdaq) that the Nasdaq Hearings Panel before which TransCode appeared on October 1, 2024, has determined to grant TransCode’s request to continue its listing on The Nasdaq Stock Market subject to certain conditions to regain compliance. Th

GlobeNewswire 4 months ago

RNAZ
+9.27%
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

The clinical trial Safety Review Committee (SRC) approved opening of Cohort 2 after review of safety data from the three patients comprising Cohort 1No significant safety or dose limiting toxicities have been reported in Cohort 1Patients are currently being evaluated for eligibility in Cohort 2TTX-MC138 is a therapeutic candidate based on microRNAmicroRNA technology was recognized with the 2024 Nobel Prize in Physiology and MedicineTransCode is the only company with an ongoing US clinical trial

GlobeNewswire 5 months ago

RNAZ
+9.27%
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

Patients currently remain on study for continued treatment with TTX-MC138 No significant safety or dose limiting toxicities reportedTTX-MC138, an antisense oligonucleotide conjugated to TransCode’s proprietary TTX delivery system, is designed to inhibit microRNA-10b, a known driver of metastasis in multiple cancersmicroRNA technology was recognized with the 2024 Nobel Prize in Physiology and MedicineTransCode is the only company with an ongoing US clinical trial targeting microRNA in cancer BOST

GlobeNewswire 5 months ago

RNAZ
+9.27%

Performance Overview

Return	RNAZ	S&P 500 (^GSPC)
YTD	-83.95%	-4.23%
1-Year	-97.63%	+7.42%
3-Year	-100.00%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TransCode Therapeutics, Inc. (RNAZ)

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SRC approves opening of TransCode’s fourth cohort in trial of TTX-MC138

TransCode Therapeutics Says Safety Review Committee Approves Opening of Fourth Group in Phase 1 Trial to Treat Metastatic Cancers

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics, Inc. Announces Results of Special Meeting

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

Transcode Therapeutics issues 21.2M shares at 37.7c in private placement

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

Transcode Therapeutics announces 1-for-33 reverse stock split

TransCode Therapeutics Open Letter to Shareholders

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

Performance Overview